Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Geovax LabsGOVX -3.69%26 3-1 Month Momentum % is -64.30% as of Sep. 04, 2026. GuruFocus rates GOVX with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,387 Biotechnology companies, Geovax Labs ranks worse than 97.69% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-04), Geovax Labs's 3-1 Month Momentum % is -64.30%.
The industry rank for Geovax Labs's 3-1 Month Momentum % or its related term are showing as below:
GOVX's 3-1 Month Momentum % is ranked worse than 97.69% of 1387
companies
in the Biotechnology industry
Industry Median: -5.77
vs GOVX: -64.30
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Geovax Labs 3-1 Month Momentum % Related Terms
GOVX vs VIVS, SPRC, SXTP: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Geovax Labs's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geovax Labs 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geovax Labs's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Geovax Labs's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geovax Labs (GOVX) has a 3-1 Month Momentum % of -64.30% as of Sep. 04, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Geovax Labs and its competitors. According to the industry distribution chart, Geovax Labs ranks #1355 out of 1387 companies in the Biotechnology industry, placing it in the top 97.7%.
Is Geovax Labs' 3-1 Month Momentum % too high?
Geovax Labs' current 3-1 Month Momentum % is -64.30%. Based on the distribution chart, Geovax Labs ranks #1355 out of 1387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Geovax Labs has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Geovax Labs' 3-1 Month Momentum % compare to VIVS and SPRC?
According to the Biotechnology industry distribution chart, Geovax Labs ranks #1355 out of 1387 companies for 3-1 Month Momentum %. This places Geovax Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Geovax Labs and its competitors. Geovax Labs's current 3-1 Month Momentum % is -64.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geovax Labs stock overvalued right now?
Geovax Labs (GOVX) has a current 3-1 Month Momentum % of -64.30%. The current 3-1 Month Momentum % is -64.30%. Geovax Labs' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Geovax Labs (GOVX), the current 3-1 Month Momentum % is -64.30% as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
26GF Score
Get the complete analysis for GOVX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GOVX has been successfully added to your 
